# Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
Canonical URL: https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-to-host-first-quarter-2026-financial-results-and-business-update-conference-call-on-may-12-2026
Ticker: AVIR
Company: Atea
Source: Atea
Published: 2026-05-05 11:00 EST
Original Source URL: https://ir.ateapharma.com
## Summary

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live

## Article Body
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live
## Recent Company News
- 2026-05-27 11:00 EST — [Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026](https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-presents-new-drug-drug-interaction-results-supporting-potential-best-in-class-profile-of-the-regimen-of-bemnifosbuvir-and-ruzasvir-for-the-treatment-of-hepatitis-c-virus-at-easl-congress-2026) — Source: Atea
- 2026-05-13 11:00 EST — [Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline](https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-to-present-three-abstracts-at-easl-2026-congress-highlighting-progress-across-viral-hepatitis-pipeline) — Source: Atea
- 2026-05-12 20:06 EST — [Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Atea
- 2026-05-05 11:00 EST — [Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026](https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-to-host-first-quarter-2026-financial-results-and-business-update-conference-call-on-may-12-2026) — Source: Atea
- 2026-03-05 21:05 EST — [Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update) — Source: Atea
## Related News
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)